Incidence of and risk factors for cognitive impairment in an early parkinson disease clinical trial cohort

Neurology

Volumn 73, Issue 18, 2009, Pages 1469-1477

  Uc, E Y ^a,b   McDermott, M P ^c,d   Marder, K S ^e   Anderson, S W ^a   Litvan, I ^f   Como, P G ^d   Auinger, P ^d   Chou, K L ^g   Growdon, J C ^h  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Department of Biostatistics and Computational Biology ^*

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f University of Louisville School of Medicine   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; SELEGILINE; TOCOPHEROL;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPTH PERCEPTION; DISEASE SEVERITY; DYSPHAGIA; EDUCATION; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; INCIDENCE; LEARNING; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROPSYCHOLOGY; PARKINSON DISEASE; PARKINSONISM; PERFORMANCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SPEECH; URINARY TRACT DISEASE; VERBAL MEMORY; VISUOMOTOR COORDINATION; WORKING MEMORY;

EID: 70449440596     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181bf992f     Document Type: Article

References (40)

1. Uc EY, Rizzo M, Anderson SW, et al. Visual dysfunction in Parkinson disease without dementia. Neurology 2005; 65:1907-1913.
2. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130:1787-1798.
3. Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study. Neurology 2009;72:1121-1126.
4. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707. (Pubitemid 47597592)
5. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602.
6. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002;51:722-729. (Pubitemid 34568851)
7. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
8. Hely MA, Reid WG, Adena MA, et al. The Sydney multi-center study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
9. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004;19:1043-1049.
10. Marder K, Tang MX, Cote L, et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.
11. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56:730-736.
12. Parkinson Study Group. Effects of tocopherol and depre-nyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
13. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained de-prenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
14. Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005;64:87-93.
15. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
16. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neu-rol 1989;46:1052-1060.
17. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65: 1863-1872.
18. Growdon JH, Kieburtz K, McDermott MP, et al. Levo-dopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients: Parkinson Study Group. Neurology 1998;50:1327-1331.
19. Kieburtz K, McDermott M, Como P, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group Neurology 1994;44:1756-1759.
20. Dissanayaka NN, Sellbach A, Matheson S, et al. Validity of Hamilton Depression Inventory in Parkinson's disease. Mov Disord 2007;22:399-403.
21. Crum RM, Anthony JC, Bassett SS, et al. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386-2391.
22. Anderson SW, Todd MM, Hindman BJ, et al. Effects of intraoperative hypothermia on neuropsychological outcomes after intracranial aneurysm surgery. Ann Neurol 2006;60:518-527.
23. Larrabee GJ, Trahan DE, Levin HS. Normative data for a six-trial administration of the Verbal Selective Reminding Test. Clin Neuropsychol 2000;14:110-118.
24. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Mac-millan Healthcare Information; 1987:153-163
25. The Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. Neurology 2000;55:66-73.
26. Edland SD, Rocca WA, Petersen RC, et al. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn. Arch Neurol 2002;59:1589-1593.
27. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease: results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008;255:255-264.
28. Parkinson Study Group. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490.
29. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.
30. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropini-role or levodopa: 056 Study Group. N Engl J Med 2000;342:1484-1491
31. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levo-dopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-472.
32. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
33. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31.
34. Holroyd S, Currie LJ, Wooten GF. Validity, sensitivity and specificity of the mentation, behavior and mood sub-scale of the UPDRS. Neurol Res 2008;30:493-496.
35. Starkstein SE, Merello M. The Unified Parkinson's Disease Rating Scale: validation study of the mentation, behavior, and mood section. Mov Disord 2007;22: 2156-2161.
36. O'Bryant SE, Humphreys JD, Smith GE, et al. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol 2008;65:963-967.
37. Stochl J, Boomsma A, Ruzicka E, et al. On the structure of motor symptoms of Parkinson's disease. Mov Disord 2008;23:1307-1312.
38. Stebbins GT, Goetz CG. Factor structure of the Unified Parkinson's Disease Rating Scale: motor examination section. Mov Disord 1998;13:633-636.
39. Chaudhuri KR, Naidu Y. Early Parkinson's disease and non-motor issues. J Neurol 2008;255 suppl 5:33-38.
40. Poewe W. Dysautonomia and cognitive dysfunction in Parkinson's disease. Mov Disord 2007;22:S374-S378